2007.11.20 – First Quantitative JAK2 V617F Mutation Kit
IPSOGEN Launches The First Quantitative JAK2 V617F Mutation Kit
20 Nov 2007
IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, announces the immediate availability of its new JAK2 MutaQuant™ Kit, a research tool intended for the accurate quantification of JAK2 V617F mutation*.
Traditionally, the diagnosis of MyeloProliferative Disorders (MPDs) is based on clinical, bone marrow, histological, immunophenotypic and cytogenetic criteria. The discovery of mutated JAK2 gene, this disease-specific molecular marker, results in both simplification of the process and increased diagnostic accuracy. Defining the presence of this mutation is now part of clinical diagnostic algorithms to prevent patient pain and avoid useless costs.
The precise quantification of JAK2 V617F mutation load will be a help to measure response to existing or new targeted therapies.
Mutated JAK2 is a breakthrough biomarker for the management of blood-based disorders because it provides clear-cut information to physicians and patients about the nature of an elevated platelet or red blood cell count which occurs frequently. IPSOGEN has developed a range of molecular assays based on mutations in the JAK2 gene, to which the company has worldwide exclusive intellectual property rights.
*The mutation affecting the Janus Tyrosine Kinase 2 (JAK2 V617F) was identified by the INSERM team of Dr. Vainchenker in 2005. This somatic mutation was found to be the most common molecular abnormality in chronic (MPD). The highest frequency occurred in patients with PV (Polycythemia Vera, >90%) or ET (Essential Thrombocythemia, 70%); the lowest frequency was found in IMF patients (chronic Idiopathic MyeloFibrosis, 50%).
IPSOGEN is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. IPSOGEN has built a comprehensive portfolio of unique products in blood cancers available in over 50 countries all over the world to leading institutions involved in cancer care. IPSOGEN products are registered as IVD in Europe.
Leveraging its expertise in blood cancers, IPSOGEN has developed, in partnership with leading cancer institutions, a pipeline of diagnostic products in breast cancer.
IPSOGEN is headquartered in Marseille, France and has its U.S. offices in New Haven, Connecticut. For more information on IPSOGEN, please visit: http://www.ipsogen.com.
JAK2 V617F mutation and uses thereof are protected by international patent application W02006045827 licensed exclusively worldwide to Ipsogen; US patent pending (US2006/0288432).
The purchase of this product does not convey any right for its use in clinical diagnostic applications or in the context of patient testing within clinical trials.
No patent rights for practising quantitative PCR, such as 5’Nuclease Process, or for using ARMS™ Technology are conveyed expressly, by implication, or by estoppel.
Ipsogen, the Ipsogen Logo and MutaQuant™ are trademarks owned by Ipsogen